# Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (

Source: https://onco.cc/trials/nct05429268/  
OnCo record `nct05429268` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Tafasitamab, Lenalidomide in diffuse large b-cell lymphoma, run by Incyte Corporation, active and no longer recruiting.

## Summary

Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) is a phase 3 interventional study registered as NCT05429268 by Incyte Corporation, with 82 participants enrolled, started 2022-12-23 and due to reach its primary completion in 2026-03-30. Interventions recorded: Tafasitamab, Lenalidomide. Conditions listed: Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05429268
- Phase: 3
- Setting: A Phase 3, Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Sponsor: Incyte Corporation
- Enrolled: 82

## Sources

- ClinicalTrials.gov NCT05429268: https://clinicaltrials.gov/study/NCT05429268

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- drugs: [Lenalidomide](https://onco.cc/drugs/lenalidomide/), [Tafasitamab](https://onco.cc/drugs/tafasitamab/)
- companies: [Incyte](https://onco.cc/companies/incyte/)

---
JSON: https://onco.cc/api/v1/entities/nct05429268.json